This content is machine translated Psoriasis: therapy with biologics and TYK-2-i Progress assessments based on current long-term and real-world data A broad spectrum of systemic agents is now available for the treatment of moderate to severe psoriasis. At this year’s DDG congress “Dermatology compact + practical”, various studies were presented...…
View Post 7 min This content is machine translated Psoriasis in difficult localizations: Nail psoriasis IL-23 and IL-17 as a target – selected study findings Although nail psoriasis remains a challenge, considerable progress has been made in both diagnostic and therapeutic terms. This is reflected, for example, in current analyses of the GUIDE and ZODIPSO...…
View Post 5 min This content is machine translated Psoriasis: System therapies in everyday practice Current real-world data at a glance The better the efficacy of a systemic treatment, the higher the patient satisfaction, especially if the risk-benefit balance is favorable. This plausible correlation is impressively underpinned by current findings from...…
View Post 4 min This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 7 min This content is machine translated Evidence-based therapy for psoriasis in difficult locations IL-23 inhibition in scalp psoriasis: what’s new? Involvement of the scalp is common in psoriasis patients and can induce considerable distress with sometimes significant effects on quality of life. In addition to new study findings on the...…
View Post 9 min This content is machine translated Psoriasis: intervening in the inflammatory cascade Advantages of early biologic therapy and oral peptide as a beacon of hope The question of whether early biologics treatment can have a lasting effect on the course of psoriasis is the focus of numerous research projects. The GUIDE study investigated the corresponding...…
View Post 9 min This content is machine translated SID Annual Meeting: Highlights Update on inflammatory dermatoses – a concentrated load of innovative power Research teams from different corners of the world presented studies that are characterized by a high level of innovation. In addition to the evaluation of already established therapy options, numerous...…
View Post 8 min This content is machine translated Psoriasis and PsA Biologics, oral peptide and trivalent nanobody – current results and trends Top-line results are available for both Icotrokinra and Sonelokimab, which attest to the great therapeutic potential of these innovative drug candidates. However, there is also extremely interesting new evidence from...…
View Post 5 min This content is machine translated Psoriasis Indications of an increased risk of “leaky gut” Psoriasis sufferers often have invisible inflammation in the small intestine along with a tendency to increased permeability of the intestinal barrier (“leaky gut”), according to recently published research from Uppsala...…
View Post 8 min This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 9 min This content is machine translated Psoriasis in locations that are difficult to treat New study data on IL-23 inhibition When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved...…
